产品名称
UM-UC-6, 08090503
biological source
human bladder
growth mode
Adherent
karyotype
Modal number of chromosomes is 51. See reference.
morphology
Epithelial
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Drug resistance in bladder neoplasms
Biochem/physiol Actions
Human transitional cell carcinoma of the bladder
STR-PCR Data: Amelogenin: X,Y
CSF1PO: 11
D13S317: 13,14
D16S539: 9,13
D5S818: 11,13
D7S820: 8,10
THO1: 7
TPOX: 9,11
vWA: 18
CSF1PO: 11
D13S317: 13,14
D16S539: 9,13
D5S818: 11,13
D7S820: 8,10
THO1: 7
TPOX: 9,11
vWA: 18
UM-UC-6 was obtained by transurethral resection of a bladder transitional cell carcinoma found in a male patient. UM-UC-6 was found to produce tumours in athymic nude mice.
Preparation Note
EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS).
Split sub-confluent cultures (70-80%) 1:4 to 1:10 i.e. seeding at 2-4x10,000 cells/cm2 using 0.05% trypsin/EDTA; 5% CO2; 37°C. Doubling time approximately 38 hours.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). Use of this product by commercial organizations may require a license agreement. Commercial customers will be contacted by cellscreening@merckgroup.com to provide further information after the order request is submitted. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.
Disclaimer
This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.